Guard Therapeutics
31.6 SEK +5.33%Be the first to follow this company
Guard Therapeutics is a developer of pharmaceuticals in the field of oxidative stress. The company focuses primarily on the research, development, and commercialization of pharmaceuticals that are intended to prevent the occurrence and complications of acute kidney damage. In preclinical studies, pharmaceuticals have been shown to protect exposed tissue and support regenerative processes. Treatment of acute kidney injuries in conjunction with heart surgery is a priority in clinical development.
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
First North Stockholm
GUARD
Daily low / high price
29.8 / 32
SEK
Market cap
317.95M SEK
Turnover
157.34K SEK
Volume
5.1K
Financial calendar
General meeting
08.05.2024
Interim report
08.05.2024
Interim report
22.08.2024
Interim report
13.11.2024
Annual report
20.02.2025
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Jan Ståhlberg | 16.4 % | 16.4 % |
M2 Asset Management AB | 11.0 % | 11.0 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Guard Therapeutics presented development strategy and new preclinical results at R&D Update
Invitation to Guard Therapeutics’ R&D Update on January 30
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools